Point-of-care fecal immunochemical testing

Point-of-care fecal immunochemical testing decreases colorectal cancer detection specificity in humans (27.3% (95% CI: 26.1–28.5%) versus 29.2% (95% CI: 27.6–30.8%); p = 0.001).

“specificities were 29.2% (95% CI: 27.6–30.8%) and 27.3% (95% CI: 26.1–28.5%), with the centralized group being slightly higher (p = 0.001).”

HumansCompared with OC-Sensor in non-paired community screening; positive threshold 100 ng/mLnear-infrared fluorescence immunochromatographyfecesn = 5,211

Application of a Quantitative POCT-FIT Based on Near-Infrared Fluorescence Immunochromatography in Population-Based Colorectal Cancer Screening: A Comparative Evaluation with a Centralized Testing System

Diagnostics·24 Sep 2026

Point-of-care fecal immunochemical testing has no effect on colorectal cancer detection sensitivity in humans (100% (95% CI: 93.2–100%) versus 98.9% (95% CI: 95.8–99.9%)).

“Sensitivities for CRC were 98.9% (95% CI: 95.8–99.9%) and 100% (95% CI: 93.2–100%), respectively, with no statistically significant difference”

HumansCompared with OC-Sensor in non-paired community screening; positive threshold 100 ng/mLnear-infrared fluorescence immunochromatographyfecesn = 5,211

Application of a Quantitative POCT-FIT Based on Near-Infrared Fluorescence Immunochromatography in Population-Based Colorectal Cancer Screening: A Comparative Evaluation with a Centralized Testing System

Diagnostics·24 Sep 2026